SCHEMBL4049744

SCHEMBL4049744

NC(=O)OCCC(=O)c1nc2ccccc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HPGD P15428 2/20 0.56
ALDH1A1 P00352 3/20 0.51
HTR1A P08908 7/20 0.51
DRD2 P14416 6/20 0.51
HTR7 P34969 6/20 0.51
SLC6A4 P31645 4/20 0.51
MAPT P10636 2/20 0.49
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5516342 0.92 DRD2 (0.55) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL12548965 0.78 NPC1 (0.63) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL10313749 0.77 RAB9A (0.67) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL28172146 0.76 DRD2 (0.62) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL19043117 0.75 DRD2 (0.61) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL369480 0.75 ALDH1A1 (0.62) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL28919881 0.74 DRD2 (0.63) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL20662518 0.74 NPC1 (0.58) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL6647582 0.74 RAB9A (0.67) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL2097484 0.74 RAB9A (0.67) NPC1RAB9ASMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1744755-B1 COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS IRM LLC (BM) 2012-12-05 EP claimed
EP-1744755-A4 COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS IRM LLC (BM) 2009-07-15 EP claimed
JP-2007535568-A 2007-12-06 JP claimed
US-20070232606-A1 Compounds and Compositions as Cathepsin S Inhibitors IRM LLC (BM) 2007-10-04 US claimed
EP-1744755-A2 COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS IRM, LLC (BM) 2007-01-24 EP claimed
WO-2005107464-A2 COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS IRM LLC (BM) 2005-11-17 WO claimed
US-20070232606-A1 Compounds and Compositions as Cathepsin S Inhibitors IRM LLC (BM) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232606-A1 Compounds and Compositions as Cathepsin S Inhibitors CTSS, CTSB, CTSF NPC1 47/4885RAB9A 480/4885SMN1; SMN2 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.